FDA grants Orphan Drug Designation to Reolysin in pancreatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted an Orphan Drug Designation to antinuclear antibody conjugated liposomal doxorubicin, developed by NanoSmart Pharmaceuticals Inc., for the treatment of Ewing’s sarcoma, a rare cancer that develops in or around children’s bones.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login